Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

Gen­uine Biotech files for HKEX list­ing: The drug de­vel­op­er, which has mul­ti­ple lo­ca­tions in Chi­na, Get free access to a limited number of articles, plus choose newsletters to get straight to ...

Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on ...

On a sunny September day in 2023, scientists at CRISPR Therapeutics invited me to peer through their microscopes. Through the ...

FDA blocks Tyche Industries & Jagsonpal Pharmaceuticals from shipping products after inspections found GMP violations in ...

HHS Secretary RFK Jr. announces vaccine schedule review despite prior pledges not to, contradicting promises made during ...

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called ...

Supernus Pharmaceuticals' depression drug SPN-820 fails Phase 2b trial due to high placebo response, causing 20% stock drop.

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe ...

Spot­light Ther­a­peu­tics, a start­up with a bold vi­sion for de­liv­er­ing CRISPR ther­a­pies in­to the body with­out the ...

The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.

The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...